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Abstract: Epithelial–mesenchymal transition (EMT) is a process that takes place during embryonic
development, wound healing, and under some pathological processes, including fibrosis and tumor
progression. The molecular changes occurring within epithelial cells during transformation to a
mesenchymal phenotype have been well studied. However, to date, the mechanism of EMT induction
remains to be fully elucidated. Recent findings in the field of intercellular communication have shed
new light on this process and indicate the need for further studies into this important mechanism.
New evidence supports the hypothesis that intercellular communication between mesenchymal
stroma/stem cells (MSCs) and resident epithelial cells plays an important role in EMT induction.
Besides direct interactions between cells, indirect paracrine interactions by soluble factors and
extracellular vesicles also occur. Extracellular vesicles (EVs) are important mediators of intercellular
communication, through the transfer of biologically active molecules, genetic material (mRNA,
microRNA, siRNA, DNA), and EMT inducers to the target cells, which are capable of reprogramming
recipient cells. In this review, we discuss the role of intercellular communication by EVs to induce
EMT and the acquisition of stemness properties by normal and tumor epithelial cells.
Keywords: extracellular vesicles; epithelial–mesenchymal transition; cancer stem cells;
intercellular communication
1. Introduction
Extracellular vesicles (EVs) are membrane-surrounded structures that act as paracrine effectors,
as they are released by cells to deliver signals to other cells. EVs can be characterized by size and the
mechanism of their biogenesis. The majority of studies investigating intercellular communication focus
on an admixture of plasma membrane-released microvesicles (microparticles) and endosome-derived
exosomes. Exosomes have sizes ranging from 40 to 150 nm [1,2], microvesicles have a heterogeneous
size: from 40 to 2000 nm [3,4]. They impact a variety of biological processes, transferring biologically
active molecules and are secreted by virtually all cells of the body [5].
EVs contain in their composition mRNA, microRNA, various proteins, and lipids, which they
deliver to neighboring cells and systemically (via the blood and lymphatic system) [6,7]. EVs mediate
the connection between cells of the body through receptor–ligand-mediated interactions and/or direct
fusion with target cells. Mesenchymal stem cell (MSC)-derived EVs have been shown to alter the
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phenotype of target cells and modulate the microenvironment [8]. Furthermore, it was shown that EVs
derived from embryonic stem cells mediate a horizontal transfer of bioactive molecules and genetic
material (including mRNA [9] and microRNA [10]) leading to the reprogramming of target cells.
Epithelial–mesenchymal transition (EMT) occurs in embryonic development, in the adult it can
be observed during wound healing, regeneration, organ fibrosis, and cancer [11–14]. However, the
specific stimulus and mechanism of EMT induction in epithelial cells is still unknown. It is known that
inflamed tissue and the tumor microenvironment contains a range of cell populations, which include
immune cells, endothelial cells, fibroblasts, and mesenchymal stroma/stem cells [15]. We believe that
intercellular communication between stem, stromal cells (tissue-specific progenitor cells, mesenchymal
stem cells), and epithelial cells contribute to the induction of EMT reprogramming and the acquisition
of a MSC phenotype.
2. Epithelial–Mesenchymal Transition
The architecture of epithelial cells is usually in the form of a sheet, with tight connections via
surface adhesion proteins and apical–basal polarity [16,17]. The key events during EMT are the loss of
this apical–basal polarity, cell–cell junctions, and adherence to the basement membrane by epithelial
cells, and the appearance of mesenchymal cell properties [17]. The epithelial cells show a reduction in
proteins related to apical dense compounds, such as occlusion, claudins, desmoplakin, and plakophilin,
as well as inhibition of E-cadherin expression during the EMT [18,19]. In contrast, the epithelial cells
increase expression of vimentin and N-cadherin and show traits characteristic of mesenchymal cells
including migration and invasion [13], supporting their ability to develop into specific tissues and
organs to mediate repair and regeneration [20,21].
Induction of EMT is regulated at the molecular level by a variety of growth factor signals,
in particular transforming growth factor-β (TGF-β), hepatocyte growth factor (HGF), epidermal
growth factor (EGF), fibroblast growth factor (FGF), Wnt proteins, IL-6, and hypoxia-inducible factor
(HIF)-1α [22–28]. These initial signals lead to changes in gene expression mediated by factors such
as Twist1, Twist2, Snail, Zeb1, Zeb2, Slug, which consequently result in mesenchymal-like changes
within the epithelial cells [29]. For example, TGF-β is a multifunctional cytokine that is considered the
main inducer of EMT. The TGF-β signaling pathway plays an important role in the regulation of cell
proliferation, differentiation, invasion, migration, apoptosis, and modification of the microenvironment
and also stimulates pathophysiological EMT and metastasis [22–24]. HGF activates the c-Met signaling
pathway, together they increase invasive and metastatic potential and ensure the survival of cancer
cells in the bloodstream in the absence of cell-to-cell contact [26]. EGF and Snail2 play an important
role in wound healing, during which signaling through the EGF receptor predominantly activates
extracellular signal-regulated kinase (ERK) pathways. It was found that the Erk5 pathway specifically
enhances Snail2 promoter activity and controls wound healing in vitro [25]. Other researchers have
shown that EGF-stimulated Smad2/3 activation promotes EMT, activates several key EMT markers,
inhibits E-cadherin expression, and improves invasion and migration in breast cancer cells [27]. FGF
is involved in the formation of the mesenchyme and during EMT in the adult it acts similarly to
increase the expression of vimentin and fibroblast-specific protein 1 (FSP1), as well as inducing matrix
metallopeptidase 2 (MMP-2) activity increasing cell mobility. FGF is also capable of causing changes in
the actin cytoskeleton capable of enabling anchorage-independent growth [28].
EMTs occur in three distinct biological processes. The first type of EMT is associated with
implantation, embryo formation, organ development, and formation of a variety of cell types with
mesenchymal phenotypes. This type of EMT generates mesenchymal cells (primary mesenchyme),
which can later undergo mesenchymal–epithelial transition (MET) with formation of secondary
epithelium [30]. EMT type 1 is detected during the formation of the neural crest, gastrulation in the
primitive deforming somatic recession, the formation of the heart valve, and other embryological
phenomena [31].
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EMT type 2 is associated with wound healing, tissue regeneration, and organ fibrosis. This type
of EMT is induced by repair-related events that usually generate fibroblasts and other related cells, in
order to repair the tissues after trauma and inflammation [32]. During wound healing at the edges of
the damaged zone, cells that have undergone EMT are found [33]. For example, keratinocytes located
in the border of a wound acquire an intermediate phenotype, which is called a “metastable” state, and
gain the ability to move around. In addition, they have markers that are characteristic of MSCs, while
in the deeper layers of the skin, this phenomenon is not observed [33].
EMT type 3 occurs in neoplastic cells that have undergone genetic or epigenetic changes. Carcinoma
cells that have undergone EMT are able to metastasize, thereby inducing the progression of cancer.
Cancer cells may undergo EMT to differing extents, retaining epithelial features and acquiring some
mesenchymal traits, or losing all epithelial features and acquiring completely mesenchymal properties.
The rate of proliferation, metastasis, likelihood of relapse, and individual response to chemotherapy
are all influenced by the switching between MET and EMT states [34]. Recovery of epithelial features
allows the proliferation of tumor cells in these secondary tumor clusters in metastases [35]. Stress (toxic,
infectious, hemodynamic, metabolic, hypoxia, nutrient deprivation, and inflammation) promotes
tumor cells to secrete a spectrum of cytokines and chemokines that favor EMT [36]. In parallel, MSCs
are recruited to inflammation sites by chemotaxis [37], communication between tumor cells and MSCs
within the tumor microenvironment may impact on EMT and is currently under study.
3. Extracellular Vesicles of Stem Cells
The composition of EVs depends on the type of parental cell and conditions under which vesicle
release occurs [38] and often reflects the specific expression profile and changes in epigenetic regulation
of the EV-producing cell [39–41].
Previous studies have shown that MSCs do not require direct contact with neighboring cells
to induce regeneration [42–44]. In this regard, the stem cell paracrine hypothesis was developed
which postulates the paracrine action of transplanted stem cells on target cell by secreting soluble
and insoluble factors into the extracellular space [45–48]. Growing evidence points that EVs possess
biological activity similar to that of the parental cell. For example, platelet-derived EVs transfer
coagulation factors and participate in blood clotting [49], embryonic stem cell-derived EVs increase
survival and improve expansion of recipient cells [9,41,50], cancer cell-derived EVs contain oncogenic
molecules and contribute to the remodeling of tumor microenvironment [51]. MSC-derived EVs are of
particular interest due to their ability to stimulate regeneration and induce angiogenesis [52–55].
Cells within a damage site secrete huge amounts of cytokines which attract MSCs toward these
areas of inflammation [56,57]. Previous studies have shown that MSC-derived EVs demonstrate
similar therapeutic effects to parental MSCs by delivery of biological active molecules to target cells.
For example, human embryonic MSC-derived EVs promote osteochondral repair [58]. Human fetal
MSC EVs promote liver regeneration by activation the IL-6/STAT3 signaling pathway and cell cycle
progression in hepatocytes after CCl4-induced injury in rats [59]. The protective effect of EVs derived
from human umbilical cord MSCs was observed using a cisplatin-induced rat nephrotoxicity model [60].
These and other studies have placed MSC-derived EVs as therapeutic tools with significant potential
in regenerative medicine.
It is known, that on the surface of EVs is present phosphotidylserine (PS) [61]. Due to the presence
of PS and tissue factor in them, EVs have procoagulant and prothrombic properties [62,63]. They
also regulate wound healing, inflammation, and vascular integrity [64,65]. Since the tumor niche
resembles the site of chronic wound healing [66], and viable cancer cells have high PS levels on the
outer surface and exhibit a wide range of surface PSs [67], EVs could be used as a therapeutic tool for
treating/detecting a tumor.
Beside protein and lipids, stem cell-derived EVs contain genetic material (mRNA, microRNA,
siRNA, DNA) [50,68] and are able to reprogram target cells by horizontal transfer of mRNA [9].
Ratajczak et al. showed that embryonic stem cell-derived EVs increase the pluripotency of target cells
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by inducing the expression of early pluripotent (Oct-4, Nanog, and Rex-1) and early hematopoietic stem
cell (Scl, HoxB4, and GATA 2) markers [9]. MSC-derived EVs deliver RNA into injured tubular cells,
altering their gene expression, and inducing dedifferentiation [69]. The accumulating data indicates
that stem cell-derived EVs carry biologically active molecules, including transcription factors, and
other genetic material capable of inducing viability and reprogramming of target cells toward a stem
cell phenotype.
4. Migration of MSCs toward Injury, Inflammation Site, and Cancerous Tissues
MSC migrate in response to chemotaxic factors including inflammatory cytokines, growth
factors, and chemokines produced by the injured tissue [70]. In fact, it was shown that adipose
tissue-derived mesenchymal stem cells (AD-MSCs) and bone marrow-MSCs (BM-MSCs) show
enhanced migration capacity toward chemokines and growth factors: platelet-derived growth factor-AB
(PDGF-AB), insulin-like growth factor-1 (IGF-1), stromal-derived factor-1 (SDF-1), macrophage-derived
chemokine (MDC), TGF-β1, and tumor necrosis factor alpha (TNF-α)—the most active MSC’s
chemoattractant [71–73]. It is known that inflammation is the reason MSCs migrate from adipose tissue
and bone marrow (stem cells niches) to blood and lymph nodes by CXCL12 (SDF-1)/CXCR4-dependent
mechanisms [72].
The phenomenon of MSC mobilization in injury sites is utilized in the treatment of many diseases.
In inflammation areas, MSCs show beneficial effects on neighboring cells via paracrine stimulation
improving cell expansion and survival and preventing apoptosis. For instance, intravenous injection of
human MSCs increases corneal allograft engraftment and prevents their rejection through the secretion
of anti-inflammatory molecule TNFα-stimulated gene (TSG) 6 [74]. BM-MSCs contribute to reducing
wound size by paracrine effects on angiogenesis and fibroblast migration [75]. Nakanishi et al. showed
that conditioned medium (CM) taken from MSCs promotes cardiac progenitor cell proliferation and
inhibits their apoptosis [76]. In addition, Linero and Chaparro demonstrated that MSC CM promoted
bone callus formation [77]. These studies demonstrated that paracrine stimulation of neighboring cells
is responsible for the beneficial effects of MSC therapy.
As a tumor is often described as being like a “chronic wound” [78–80], the hypoxic conditions and
high concentration of cytokines and growth factors IL-1α, IL-1β, IL-6, FGF-2, IGF-1, TGF-β, VEGF-A,
HIF-1α, EGF, TGF-α are a likely trigger for MSCs recruitment to tumor microenvironments [79,81,82].
These same factors, which act to control wound healing, are critical not only in MSC recruitment
but also in their function. For example, TGF-β1 expressed by prostate cancer cells mediates
MSC transdifferentiation into tumor-supporting carcinoma-associated fibroblasts (CAFs) [83–85].
Other studies demonstrate some MSCs integrate in a tumor and subsequently transform into
tumor-associated MSCs (TA-MSCs). TA-MSCs show a stronger tumor-promoting capacity through
microenvironment modulation [86]. MSCs migrate to the tumor microenvironment in much the same
way as observed at sites of inflammation and in both cases, they effect to resident cells via paracrine
stimulation [37,70–77,79,81,82,87–95] (Figure 1). MSC tropism to tumors has been utilized as a means
of delivering an antitumor therapy. Ren et al. showed that i.v. injection of MSC-overexpressing
lipocalin-2 led to the significant reduction of tumor volume in a model of lung cancer [96]. Intranasal
injection of MSCs was found to have strong tropism to gliomas and potentially could be used to target
brain tumors [97]. The potential of MSCs to deliver drugs has been demonstrated in a number of
tumor types. Systemic delivery of MSC-overexpressing IL-12 significantly inhibited the growth of
established subcutaneous renal tumors [98]. Furthermore, modification of MSCs to express TRAIL led
to long-term remission of renal cell carcinoma [99].
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that expression of Twist1 is associated with the acquisition of stemness properties by tumor cells and 
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proposed MET, which is necessary for the development of metastatic sites [100]. Indeed, suppression 
of Snail1, Twist1, or Prrx1 attenuates the EMT and promotes the colonization of the metastatic site by 
tumor-initiating cells [102,104,105]. 
The molecular changes occurring during EMT have been well studied. However, the driver of 
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regulate EMT in MCF7 (breast cancer cells) by targeting the ZEB/miR-200 regulatory loop [107]. 
Research has shown that direct co-culture of breast or gastric cancer cells with human BM-MSCs 
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Figure 1. Mesenchymal stem cell (MSC) migration toward tumor/injury site. Tumors or inflamed tissues
release the chemokines and growth factors inducing MSC chemotaxis. Migrated MSCs demonstrate
beneficial effects on resident cells [37,70–77,79,81,82,87–95].
Tumor-infiltrating MSCs (TA-MSCs) are thought to be important contributors to EMT via direct
cell–cell contact and through paracrine mechanisms such as the secretion of bioactive molecules and
extracellular vesicles EVs [15].
5. Mesenchymal Stem Cells in Epithelial–Mesenchymal Transition and Related Processes
Ectopic expression of EMT transcription factors (TFs), including Twist1 and Snail1 was conducted
in order to assess the contribution of EMT to the proces of metastasis. It was ob erved that expression
f Twist1 is associated with the acquisi f stemness properties by tumor cells and increased
metastasis [100,101]. However these factors did not contribute to the metastatic progression [102,103].
Constitutiv expre sion of EMT-TFs induc a permanent state of EMT and blocks the proposed MET,
which is nece sary for the d velopment of metastatic sites [100]. I deed, suppression of Snail1, Twist1,
or Prrx1 attenuates the EMT and promotes the colonization of the meta tatic site by tumor-initiati g
cells [102,104,105].
The molecular changes occurring during EMT have been well studied. However, the driver of
EM r mains nclear. The presence of MSCs in the tumor stroma i able to stimulate EMT of cancer
cells. In models of breast canc r, bone marrow-d rived MSCs promote de novo lysyl oxidase (LOX)
production from breast tumor cells, this in turn stimulates Twist transcripti n and triggers EMT. The
acq isition of stemness propertie through Twi t-induc d EMT results in increased metastasis to both
the lungs and bones [106]. Similarly, TGF-β1 secreted by human AD-MSCs has been shown to regulate
EMT in MCF7 (breast cancer cells) by targeting the ZEB/miR-200 regulatory loop [107]. Research
has shown that direct co-culture of b east or gastric ca cer cells with human BM-MSCs resulted in
th upregulation of EMT markers N-cadherin, vimentin, Twist, and Snail and t e downregulation
of E-cadherin [108,109]. The authors showed that the factors secreted by MSCs are responsible
for changes in epithelial/mesenchymal cell marke , the morphology nd growth pattern of breast
cancer cells, the incr ased expr ssion of genes associated with invasi n and migration, angiogenesis,
and anti-apoptosis [108]. MSC supernatant has been used to induce EMT in human hepatocellular
carcinoma cells (HCC). HCC cells were grown in CM from MSCs pretreated with TNF-α and IFN-γ.
HCC lls showed marked changes in mole ular markers and functional characteristics associated with
EMT, such as increased migration nd invasion in both in vitro and in vivo [110]. CM of spheroid MSC
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cultures has also been used to demonstrate the effects of MSC-secreted factors. Klopp et al. treated
human mammary epithelial cells (HMECs), MCF-7 and SUM149 (breast cancer cells), with MSC-CM.
This led to an increase in the formation of the mammosphere by 6.4–21 times. The mammospheres
had lower levels of cell adhesion protein, E-cadherin, increased expression of N-cadherin, vimentin,
Snail, and Slug, all characteristic of a pro-invasive mesenchymal phenotype [111]. A previous study
demonstrated that the CM of human MSCs (hMSCs) promoted the proliferation, migration, and
invasion of PC-3 (prostate cancer cells) by upregulating of the expression of matrix metallopeptidase 2
(MMP-2) and matrix metallopeptidase 9 (MMP-9). Blocking TGF-β blunted the pro-oncogenic function
of hMSCs. These results suggest that hMSCs play a pro-oncogenic role in the growth of human prostate
cancer by producing TGF-β [112].
Cell-to-cell contact and factors secreted by MSCs have a significant effect on tumor cells and
mediating EMT. EVs form an important element of the factors secreted by MSCs. These unique mediators
of MSC cell-to-cell communication contain inducers of EMT, such as TGF-β, TNF-a, IL-6, TSG101,
RAC-alpha serine/threonine-protein kinase (AKT), integrin-linked kinase (ILK) 1, b-catenin, casein
kinase II (CK2), annexin A2, integrin-3, caveolin-1, and matrix metalloproteinases [113–120]. Luga et al.
found that EVs produced by breast cancer-associated fibroblasts in the tumor microenvironment
contain WNT signaling pathway proteins and are able to activate the migration and metastasis of
breast tumor cells [121]. Aga et al. demonstrated that EVs carrying latent membrane protein 1 (LMP1)
modulate the expression of EMT markers in recipient cells (N-cadherin expression is increased and
E-cadherin is decreased) [122] (Figure 2). Whilst Zhou et al. showed EVs produced by human umbilical
cord MSCs significantly enhance the proliferative, migratory, and invasive properties of breast cancer
cells (MDA-MB-231 and MCF-7) through the induction of EMT via the ERK pathway in vitro [123].
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Figure 2. Schematic representation of the epithelial–mesenchymal transition (EMT) mechanism. Tumor
cell undergo EMT under the influence of MSC-derived extracellular vesicles (EVs), with subsequent
migration to a metastatic niche, returning to the epithelial phenotype (mesenchymal–epithelial transition
(MET)) and the formation of a new metastatic site.
In metastatic sites, a reversal to a more epithelial state, mesenchymal–epithelial transition, is
usually necessary [124]. As with EMT, the drivers of MET are yet to be fully determined [125].
Potentially the loss of secreted factors such as EVs from TA-MSCs may be one drivers of the reversal
MET process, as once the cancer cells have migrated from the primary tumor, they no longer face the
signals they experienced within the primary tumor microenvironment.
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The understanding of the trigger mechanism of EMT of cancer cells is essential for the successful
antitumor therapy. To prevent tumor dissemination, drugs and strategies targeted on the EMT program
might be developed. Thus, the possible use of natural or modified/loaded EV MSCs to inhibit factors
inducing EMT will provide an opportunity to control the process of tumor metastasis For example,
in the future, in EVs, you can try to download the compounds: apigenin [126], melatonin [127],
miR-711 [127], which have already shown the ability to inhibit migration and invasion, as well as the
emergence of EMT of tumor cells. Moreover, to increase the efficiency of the delivery of EV contents,
one can use targeting with recombinant proteins without affecting the integrity of the EVs, as was
shown in the article by Kooijmans et al. [38].
6. Conclusions
Current evidence clearly supports a role for MSCs in the EMT process via both direct cell contact
and through secreted factors. However, the full extent of MSCs and their paracrine effects, particularly
via EVs, in the process of driving EMT and MET requires further scrutiny. A thorough study of the
components of the molecular composition of EVs will help determine which of them contribute most
to the induction and progression of EMT and MET. This is an important area of research since the
potential of utilizing MSC EVs to manipulate EMT/MET transitions offers a potentially significant
therapeutic opportunity to target both metastatic cancer and other chronic inflammatory diseases
including chronic, non-healing wounds.
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